Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Type A Clear all

Conditions: Influenza
Interventions: cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: Oseltamivir Phosphate, ADS-8902; Drug
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: COVID-19/ Flu A&B Rapid Panel; Device
Lead sponsor: Abbott Rapid Diagnostics Jena GmbH; Industry
Eligibility: Not listed
Enrollment: 2,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
Interventions: Aptitude Medical Systems Respiratory Panel Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Trussville, Alabama

Conditions: A/Vietnam/H5N1 Influenza Virus
Interventions: 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk); Biological · Other
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more

Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxoviridae, H5N1 Virus
Interventions: VRC-AVIDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
Interventions: Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections; Diagnostic Test
Lead sponsor: Baebies, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Influenza
Interventions: AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Influenza
Interventions: A/Texas; Biological
Lead sponsor: Daniel Hoft, MD, PhD; Other
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza, Influenza Vaccines
Interventions: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Stockbridge, Georgia • Rockville, Maryland • Madison, Wisconsin

Conditions: Influenza A, Influenza B, COVID - 19, RSV
Interventions: Investigational Flu A/B Covid-19 and RSV Diagnostic Test; Diagnostic Test
Lead sponsor: iHealth Labs inc; Industry
Eligibility: 6 Months and older
Enrollment: 1,119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 21
States / cities: Birmingham, Alabama • Trussville, Alabama • Dublin, California + 17 more

Conditions: Influenza A Virus, H1N1 Subtype
Interventions: Zanamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza Infection
Interventions: A/Mallard/Ohio-99/MM4/1989 H10N7; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: COVID-19, Influenza A, Influenza B
Interventions: MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o); Diagnostic Test
Lead sponsor: Medical Group Care, LLC; Industry
Eligibility: 2 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza A
Interventions: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,977 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 51
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 20 Years to 49 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Influenza virus vaccine (Pediatric formulation); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
Interventions: LumiraDx SARS-CoV-2 & Flu A/B; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: 2 Years and older
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cullman, Alabama

Conditions: Influenza
Interventions: Influenza A/H5N1 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 9 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Torrance, California • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Influenza, Human, Respiratory Syncytial Virus Infections
Interventions: Swab; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: Not listed
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Encinitas, California • Madera, California + 17 more

Search by objective public record fields.

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

St. Jude Open Label H5 Trial

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

Safety Study of Avian Flu Vaccine

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Pilot Influenza Challenge Study

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites